The American Urology Association (AUA), in 2023, recommended that clinicians should offer a baseline PSA test to people between ages 45 to 50 years, cancer screening beginning at age 40 to 45 years for people at increased risk (Black ancestry, germline mutations, strong family history of PCa), and regular prostate cancer screening every 2 to 4 years to people aged 50 to 69 years [25]. Here, KLK3 is linked to posterior cortical atrophy.